Key facts
- It has raised $34.0M.
- Notable investors include Earlybird Venture Capital, Double Point Ventures, Penn Center for Innovation, Savanne Life Sciences.
- 1 investment vehicle was formed to buy GEMMABio shares in the last 12 months, reporting $693K sold to 10 investors, per SEC Form D filings.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for GEMMABio
- ·The full record, as it builds
Funding rounds
No funding rounds for GEMMABio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Secondary demand: investment vehicles
from SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy GEMMABio shares, reporting $693K sold to 10 investors. Most recent filing Mar 2026. Vehicles like these are how secondary buyers pool demand for a name; a rising count is a demand signal.
About GEMMABio
Operator of a therapeutics company intended to develop gene therapies for those living with rare diseases. The company serves as the research and innovation arm to speed the research of and global access to gene therapy and therapeutics to patients worldwide, enabling healthcare industry to bring gene therapy discoveries from the bench to the bedside faster and affordably.
- Sector
- Healthcare
- HQ
- Philadelphia, PA, United States
- Founded
- 2024
- Employees
- 64
- Website
- gemmabiotx.com/
- Ownership
- Privately Held (backing)
GEMMABio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GEMMABio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GEMMABio in its N-PORT filings yet. We sweep new filings monthly.